The Pragmatic AI Pivot
Recent AI-related news is signaling a shift in the bio/pharma industry’s digital transformation from speculative molecule generation toward grounded biological context and downstream manufacturing execution.
The bio/pharma industry has undoubtedly been bitten by the artificial intelligence (AI) bug. During the last few weeks of June alone there has been a spate of AI-related news stories, such as Bayer and Iambic’s collaboration on AI drug discovery (1), Xellar Biosystems’ USD 50 million financing raise (2), and the launch of ReefIQ — a biological context layer for AI drug discovery — by MindWalk Holdings (3), to identify a few.
On the surface, the flurry of recent news appears to be similar to many others that have been published before, where potentially revolutionary futures are promised and in fact, only incremental gains are actually achieved. Yet, beneath the headlines, a more critical maturity shift seems to be breaking through as industry starts to move away from the inflated expectations of AI and into an era of pragmatism about the digital transformation.
Moving Beyond Generative Hype
Initial enthusiasm around AI was focused on generative chemistry, where algorithms are employed to produce millions of novel molecular structures. However, while the output of this approach has been impressive in terms of scale, the molecules being identified are not always feasible for development (4,5).
One challenge facing these AI-identified molecules is the inherent complexity of human biology. Seeking to overcome this hurdle in particular, MindWalk has developed the ReefIQ platform, which works by connecting discovery data, evidence, and program knowledge to biological relationships.
"In life-sciences AI, the durable advantage is not the model a team licenses but the biological context it can reason over. Biology is connected by evolutionary constraint; discovery data arrives fragmented across files and systems, and that gap is where insight is lost,” said Dr. Jennifer Bath, PhD, CEO and President of MindWalk Holdings Corp, in a company press release (3). “ReefIQ is designed to close it, preserving what every program learns, including the programs that fail, as governed context rather than isolated files. In a regulated setting, that is what makes reasoning trustworthy, and trustworthy is what compounds into the clinic.”
This focus on grounding machine learning in tangible biological reality is also the driving force behind Xellar Biosystems’ USD 50 million Series A and A+ financing round at the end of June (6). While computational models possess immense power, they are ultimately restricted by the data used to train them. Traditional animal models and simplified in vitro assays frequently fail to translate to human outcomes, creating a data gap that limits AI’s predictive capacity.
“AI alone will not revolutionize drug discovery,” noted Xin Xie, Ph.D., founder and CEO of Xellar Biosystems, in a news story on the finance raise (6). “The future belongs to organizations that can generate high-quality human data at scale. We believe organ-on-chip systems, automation, and AI must work together in a closed-loop flywheel. Our mission is to transform biology from something we observe into something we can systematically understand, model, and ultimately predict.”
Bridging the Discovery to Downstream CMC Gap
While these structural advancements are reshaping the early phases of discovery, those navigating development and chemistry, manufacturing, and controls (CMC) understand that a molecule identified quickly can get stuck during formulation. The true maturation of AI in the bio/pharma sector will ultimately be measured by its ability to break downstream bottlenecks, particularly within advanced oral solid dosage engineering (7).
Fortunately, this shift from speculation to operational utility is quietly gaining ground across the manufacturing suite. Rather than relying on traditional, empirical trial-and-error bench work to formulate fragile, poorly soluble, or highly potent new chemical entities, advanced machine learning models are being deployed to predict excipient-API compatibilities and solid-state stability mechanisms before physical blending even occurs (8).
Furthermore, the introduction of mechanistic digital twins of unit operations — such as high-speed tablet presses and continuous blenders — is allowing engineering teams to virtually simulate complex powder dynamics. Common manufacturing defects like capping, lamination, or powder segregation can now be modeled and corrected long before a product ever enters physical tech transfer, which avoids wasting costly API (9).
Confronting the Regulatory Frontier
Nevertheless, as the industry embraces this digital transformation, a healthy dose of skepticism remains necessary. The ultimate destination for any AI-optimized formulation or molecule is a highly regulated human clinical trial, and global health authorities such as the FDA and EMA maintain inherently cautious frameworks regarding computational data (10).
Many deep learning models operate by delivering highly optimized outcomes without a transparent, traceable pathway demonstrating how such conclusions were reached. To secure regulatory confidence, avoid validation bottlenecks, and ensure absolute data integrity, developers cannot treat AI as a complete substitute for physical validation. Computational algorithms must complement, rather than replace, rigorous quality-by-design principles and explainable, mechanistic science.
Ultimately, the activity witnessed across June 2026 is a strong indication that the industry is successfully restructuring its relationship with digital tools. The companies that thrive over the next decade will not be those using AI as a marketing buzzword to bolster financing rounds, but those that successfully weave computational intelligence, human-relevant biology, and robust CMC execution into a unified, predictable scientific workflow.
References
Iambic Therapeutics. Bayer and Iambic Collaborate to Advance Drug Discovery with AI. Press Release, June 22, 2026.
Insilico Medicine. Insilico Medicine and SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders. Press Release, June 21, 2026.
Business Wire. MindWalk Holdings Corp. (NASDAQ: HYFT) Launches ReefIQ, a Biological Context Layer for AI Drug Discovery. News Release, June 10, 2026.
Filella-Merce, I.; Molina, A.; Díaz, L.; et al. Optimizing Drug Design by Merging Generative AI with a Physics-Based Active Learning Framework. Commun. Chem. 2025, 8, 238.
Jusoh, A.S.; Remlis, M.A.; Mohamed, M.S.; Cazenave, T.; Fong, C.S. How Generative Artificial Intelligence Can Transform Drug Discovery. Eur. J. Med. Chem. 2025, 295, 117825.
Citybiz. Xellar Biosystems Raises $50 Million Series A to Advance AI-Driven Drug Discovery Platform. News Story, June 30, 2026.
Jiang. J.; Ma. X.; Ouyang, D.; Williams III, R.O. Emerging Artificial Intelligence (AI) Technologies Used in the Development of Solid Dosage Forms. Pharmaceutics 2022, 14 (11), 2257.
Jia, S.; Wang, N.; Yang, R.; et al. FormulationDE: An Updated Artificial Intelligence System for Drug–Excipient Compatability Prediction. AAPS Open 2026, 12, 20.
Jajcevic, D.; Remmelgas, J.; Toson, P.; et al. Development of a High-Fidelity Digital Twin Using the Discrete Element Method for a Continuous Direct Compression Process. Part 1. Calibration Workflow. 2024, 666, 124796.
European Medicines Agency (EMA). EMA/CHMP/83833/2023 Reflection Paper on the Use of Artificial Intelligence in the Lifecycle of Medicinal Products. Sept. 9, 2024.